The chronic bronchitis is defined as the inflammation of the bronchi that lasts for more than 3 months for consecutive 2 years. The bronchi are the tubes which carry air in to the lungs. The major symptom of bronchitis is persistent cough associated with mucus expectoration, headache, nasal congestion, sore throat and fatigue. Risk factors for bronchitis include irritants, chemicals, air pollution and smoke. There are mainly two types of bronchitis–acute (short term) and chronic (long term). Acute bronchitis is mainly caused due to viral infection and last for around 10 to 15 days. The first line of treatment for acute bronchitis is symptomatic treatment, however, if the symptoms persists, antimicrobial therapy is advised. Mostly antibacterial such as clarithromycin or azithromycin are administered.
The treatment for chronic bronchitis includes bronchodilators and steroids. The bronchodilators such as albuterol (Ventolin, Proventil, Vospire, ProAir), metaporterenol (Alupent), formoterol and salmeterol, helps in relaxation of the smooth muscles of the bronchi which helps in expansion of the inner wall for better airway passage. Moreover, certain steroids are used such as prednisone, methylprednisolone that help in reducing the inflammation consequently helping in reduction of mucus secretion. Sometimes antibiotics are administered especially when there is an exacerbation of chronic bronchitis caused as a result of bacterial infection. Furthermore, PDE4 inhibitors are also being tested for their use in treatment of chronic bronchitis. For instance, Arcapta Neohaler received a FDA approval from Novartis
To remain ‘ahead’ of your competitors, request for a sample
Bronchitis Treatment Market: Drivers and Restraints
Bronchitis treatment market is driven by sedentary lifestyle, addiction to cigarette smoke and chemical pollutants. Guidelines from the World Health Organization (WHO), stringent regulations to pollutant emission control, adherence to various international protocol such as Montreal Protocol and World Bank– Millennium Development Goal is expected to boost overall bronchitis treatment market.
Bronchitis Treatment Market: Overview
Significant increase in respiratory disorders along with alarming rise in chemical pollutants is expected to drive the demand for effective bronchitis treatment. The market is expected to witness healthy growth during the forecast period.
Bronchitis Treatment Market: Region- wise Outlook
The global Bronchitis Treatment Market is expected to register significant CAGR during the forecast period. Depending on geographic regions, global Bronchitis Treatment Market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, and Asia Pacific excluding Japan, Japan and Middle East & Africa
North America dominates the global Bronchitis Treatment Market due to good awareness of healthcare in people and having good health care setup. Europe occupies second place in this market with its new regulations in the major economies. Asia Pacific is expected to witness fastest growth and is expected to gain significant market share over the forecast period.
Bronchitis Treatment Market: Key Players
Major players of this market include
- Pfizer Inc.
- GlaxoSmithKline Pharmaceuticals Limited
- Sanofi Aventis
- Boehringer Ingelheim
- Dr. Reddy’s Laboratories Ltd
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1277
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia Pacific (China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Bronchitis Treatment Market: Segmentation
Bronchitis Treatment Market further segmented into following types
By Treatment:
- Drugs
- Oxygen therapy
By Class of Drugs:
- Antibiotics
- Bronchodilators
- Mucolytics
- Anti-inflammatory Drugs
By End User
- Hospitals
- Clinics
- Drug stores
For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1277
Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint